Trypanosome+cruz,+calpaan+like+cysteine+peptidase,+putative+...+Hannah+Zawatski

Trypanosoma cruzi, calpain-like cysteine peptidase, putative GeneDB / Tc00.1047053445281.9
 * Target (protein/gene name):**
 * NCBI Gene # or RefSeq#:**
 * Protein ID (NP or XP #) or Wolbachia#:**

[|TcCLB.506983.48:pep.] || T. Cruzi T. Cruzi are a species of parasitistic euglenoids that live off the blood of another organism. The parasites bore in the tissue of other organisms and use their blood as a source of food. In humans, T. cruzi are responsible for chagas disease. Chagas disease spreades through insects and can infect any host. The symptoms of Chagas disease are fairly mild, just a fever or swelling. If left untreated, however, Chagas disease can cause congestive heart failure. __http://www.tdrtargets.org/targets/view?gene_id=35176__ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060929/ Is it a monomer or multimer as biological unit **? (make prediction at**@http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html ):
 * [|TcCLB.506983.39:pep.]
 * Organism (including strain):**
 * Etiologic Risk Group (see link below):**
 * Link to TDR Targets page (if present):**
 * Link to Gene Database page (NCBI, EuPath databases -e.g. TryTryp, PlasmoDB, etc - or PATRIC, etc.)**
 * Essentiality of this protein:**

Tc00.1047053445281.9 has essentiality data Gene/Ortholog: Tb11.v4.0001 (OG4_14047); Phenotype: no significant loss or gain of fitness in bloodstream forms (3 days); Source study: alsford Gene/Ortholog: Tb11.v4.0001 (OG4_14047); Phenotype: significant gain of fitness in bloodstream forms (6 days); Source study: alsford Gene/Ortholog: Tb11.v4.0001 (OG4_14047); Phenotype: no significant loss or gain of fitness in procyclic forms; Source study: alsford Gene/Ortholog: Tb11.v4.0001 (OG4_14047); Phenotype: no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms; Source study: alsford Gene/Ortholog: Tb11.47.0036 (OG4_14047); Phenotype: significant loss of fitness in bloodstream forms (3 days); Source study: alsford Gene/Ortholog: Tb11.47.0036 (OG4_14047); Phenotype: significant loss of fitness in bloodstream forms (6 days); Source study: alsford Gene/Ortholog: Tb11.47.0036 (OG4_14047); Phenotype: significant loss of fitness in procyclic forms; Source study: alsford Gene/Ortholog: Tb11.47.0036 (OG4_14047); Phenotype: significant loss of fitness in differentiation of procyclic to bloodstream forms; Source study: alsford Gene/Ortholog: Tb11.47.0035 (OG4_14047); Phenotype: no significant loss or gain of fitness in bloodstream forms (3 days); Source study: alsford Gene/Ortholog: Tb11.47.0035 (OG4_14047); Phenotype: no significant loss or gain of fitness in bloodstream forms (6 days); Source study: alsford Gene/Ortholog: Tb11.47.0035 (OG4_14047); Phenotype: no significant loss or gain of fitness in procyclic forms; Source study: alsford Gene/Ortholog: Tb11.47.0035 (OG4_14047); Phenotype: significant gain of fitness in differentiation of procyclic to bloodstream forms; Source study: alsford Gene/Ortholog: Tb11.57.0008 (OG4_14047); Phenotype: significant loss of fitness in bloodstream forms (3 days); Source study: alsford Gene/Ortholog: Tb11.57.0008 (OG4_14047); Phenotype: significant loss of fitness in bloodstream forms (6 days); Source study: alsford Gene/Ortholog: Tb11.57.0008 (OG4_14047); Phenotype: no significant loss or gain of fitness in procyclic forms; Source study: alsford Gene/Ortholog: Tb11.57.0008 (OG4_14047); Phenotype: significant loss of fitness in differentiation of procyclic to bloodstream forms; Source study: alsford

0.1  3.4.22.51 http://www.brenda-enzymes.org/enzyme.php?ecno=3.4.22.51
 * Complex of proteins?:**
 * Druggable Target (list number or cite evidence from a paper/database showing druggable in another organism):**
 * EC#:**
 * Link to BRENDA EC# page:**

No assay information for this target
 * Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):**
 * -- link to Sigma (or other company ) page for assay (see Sigma links below)**
 * -- -or link (or citation) to paper that contains assay information**
 * -- links to assay reagents (substrates) pages.**
 * --- List cost and quantity of substrate reagents, supplier, and catalog #**

-- PDB # or closest PDB entry if using homology model: ,, -- For Homology Model option: Show pairwise alignment of your BLASTP search in NCBI against the PDB Query Coverage: Max % Identities: % Positives Chain used for homology:
 * Structure (PDB or Homology model)**

code format="sequence"        10         20         30         40         50 MTEIKYENGQ PTFEGPTVVK CFKDNGNGLL FRIVNEEKKQ WAFYNDTKEY 60        70         80         90        100 NMNVKAAFGK DSKVEPLGST KMEKDEATGE FKCEVQVPPL ATVLFVEGEP 110 NGYKLNFEAN PVAK code 12,848 Da
 * Current Inhibitors:**
 * Expression Information (has it been expressed in bacterial cells):**
 * Purification Method :**
 * Image of protein (PyMol with features delineated and shown separately):**
 * Amino Acid Sequence (paste as text only - not as screenshot or as 'code'):**
 * length of your protein in Amino Acids: 114**
 * Molecular Weight of your protein in kiloDaltons using the [|Expasy ProtParam] website**
 * Molar Extinction coefficient of your protein at 280 nm wavelength:**
 * TMpred graph Image** ( @http://www.ch.embnet.org/software/TMPRED_form.html ). Input your amino acid sequence to it.

[|download.php]


 * CDS Gene Sequence (paste as text only):**
 * GC% Content for gene:**
 * CDS Gene Sequence (codon optimized) - copy from output of Primer Design Protocol (paste as text only):**
 * GC% Content for gene (codon optimized):**

Do Not Need this info for Spring (but still copy these lines to your Target page for now) -- Ask a mentor, Dr. B, or a fellow researcher -how to link a GDocs file if you are not sure how to.
 * Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers):**
 * ( link to DNA Works output text file - ** that should be saved in your Google Docs folder after you did the primer design protocol)


 * Primer design results for 'tail' primers (this is just 2 sequences):**